Recent studies showed that in curcumin-resistant hepatic carcinoma cells, the Chk1-associated G2/M cell cycle block might contribute to curcumin resistance, with Chk1 being a potential target for improving the therapeutic efficacy of curcumin [116]. This evidence concerns the gene CHEK1 and hepatocellular carcinoma.